Secondary Efficacy Endpoints
Treatment response: Significant improvement in biomarkers compared to placebo
Beyonttra provided higher serum TTR levels and reduced the increase in NT-proBNP levels from baseline compared to placebo
Serum TTR levels
were significantly and promptly increased by day 28 (9.1 ± 0.3 mg/dL) in the BEYONTTRA® group, and this elevated level was sustained through to 30 months'
NT-proBNP levels
were 47% lower in the BEYONTTRA® group compared to placebo at Month 30
Adapted from Ji AX, et al. 2023.
Beyonttra supports patients to slow the decline of their QOL
Beyonttra showed a clinically relevant, statistically significant improvement in KCCQ-OS at Month 30 compared to placebo
Change in KCCQ-OS from baseline to Month 42*
Adapted from Judge DP, et al 2024
* Data are for the full analysis set. The full analysis set included the modified intention-to-treat population in ATTRibute-CM, which was defined as all participants who were randomised to acoramidies or placebo, received ≥ 1 dose of acoramidis or placebo, had ≥ 1 efficacy evaluation after baseline, and had baseline eGFR of ≥ 30 mL/min/1.73 m. The arrow at Month 30 indicates the final follow-up time point in ATTRibute-CM and the beginning of the OLE study.
Serum TTR levels from Attribute-CM trial
Beyonttra significantly increased serum TTR levels at Month 30 compared to placebo with increase observed at day 28
Change in serum TTR from baseline to Month 30*
Adapted from Gillmore JD, et al. 2024
* Observed measurements without any imputation. No adjustment was made for early discontinuation for any reason, including death.
Abbreviations:
PP-BEY-IE-0039-1 | November 2025
▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professional are asked to report any suspected adverse reactions.